🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Dendrobine attenuates postoperative cognitive dysfunction by inhibiting Runx1-mediated NF-κB signaling pathway.

PMID: 41616945 · DOI: 10.1016/j.brainresbull.2026.111746 · Brain research bulletin, 2026 · Dong Ji, Qingyu Sun, Chengcheng Zhang, Mingyi Zang, Wei Xiao, Jie Liu, Xiaohua Fan, Hongbing Wang
📄 Abstract

Postoperative cognitive dysfunction (POCD) in older adults is strongly linked to neuroinflammation driven by microglial activation and NF-κB signaling. Runx1 has emerged as an upstream regulator of NF-κB, but its role in POCD is unknown. Dendrobine, a sesquiterpenoid alkaloid from Dendrobium species, exhibits anti-inflammatory and neuroprotective activity. POCD was induced in aged C57BL/6 mice via sevoflurane anesthesia combined with exploratory laparotomy. Dendrobine (10 or 20 mg/kg) was administered, and cognitive outcomes were evaluated by Morris Water Maze and Novel Object Recognition. RNA sequencing, Western blotting, immunofluorescence, and in vitro microglia-neuron co-culture systems were employed to investigate inflammatory responses, apoptosis, synaptic plasticity, and signaling pathway activation. Functional roles of Runx1 were validated via siRNA knockdown, pharmacological inhibition (Ro5-3335), and overexpression in BV2 cells. Dendrobine improved spatial and recognition memory in POCD mice, reduced hippocampal microglial activation, proinflammatory cytokine expression (TNF-α, IL-1β, IL-6), and neuronal apoptosis while enhancing synaptic protein levels (BDNF, PSD95, SYN1). Transcriptomic and KEGG analyses revealed suppression of NF-κB signaling by dendrobine, with Runx1 identified as an upstream modulator. Dendrobine downregulated Runx1 expression in vivo and in vitro. Runx1 inhibition enhanced dendrobine's anti-inflammatory effects, whereas RUNX1 overexpression abolished them. Dendrobine ameliorates POCD by inhibiting the Runx1/NF-κB signaling pathway, suppressing neuroinflammation, promoting synaptic resilience, and preventing neuronal apoptosis. Runx1 appears to act as a key upstream mediator of NF-κB signaling in POCD. Targeting the Runx1/NF-κB axis represents a promising strategy for perioperative neuroprotection.

Confidence: 0.42 · 21 полей извлечено
Идентификация (6 полей)
Target
Runx1
0.95
Alt. target
RUNX1
0.90
Protein family
Runt-related transcription factor family
0.85
Functional class
Transcription factor
0.90
Subcellular loc.
Nucleus
0.80
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
Inhibits Runx1-mediated NF-κB signaling pathway
0.95
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
Suppresses neuroinflammation by reducing microglial activation and proinflammatory cytokines (TNF-α, IL-1β, IL-6)
0.90
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
Prevents neuronal apoptosis
0.85
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
NF-κB signaling pathway, Runx1
0.90
Downstream (physiol)
Reduced microglial activation, enhanced synaptic proteins (BDNF, PSD95, SYN1), decreased proinflammatory cytokines
0.85
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
BV2 microglia cells, microglia-neuron co-culture system
0.95
In vivo
Aged C57BL/6 mice with POCD induced by sevoflurane anesthesia and exploratory laparotomy; dendrobine administered at 10 or 20 mg/kg; cognitive tests: Morris Water Maze, Novel Object Recognition
0.95
In silico
Transcriptomic and KEGG analyses
0.90
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
Aged C57BL/6 mice
0.95
Diet/model
POCD model: sevoflurane anesthesia + exploratory laparotomy
0.95
Клиника (11 полей)
Drug
Dendrobine
1.00
Indication
Postoperative cognitive dysfunction
1.00
Patient subgroups
Older adults
0.90
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
Preclinical
0.90
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
Improved spatial and recognition memory, reduced hippocampal microglial activation, reduced proinflammatory cytokine expression (TNF-α, IL-1β, IL-6), reduced neuronal apoptosis, enhanced synaptic protein levels (BDNF, PSD95, SYN1)
0.90
Approved
False
0.90